#Japan #Tokyo #RIKEN #JST #Mitate Zepto

Mitate Zepto Technica Joins Next-Gen AI Semiconductor R&D Program

On April 20, 2026, Mitate Zepto Technica, Inc. (MZT), situated in the vibrant Shibuya district of Tokyo, announced its collaboration with the Japan Science and Technology Agency (JST). This partnership revolves around the pioneering initiative "Next-Generation Edge AI Semiconductor Research and Development Program," where MZT is designated as a social implementation and commercialization partner. This program aims to push the boundaries of edge intelligence for artificial intelligence in scientific applications, with a key focus on genome analysis.

Driving Innovation through RASEN

MZT is set to play a leading role in translating research findings into practical solutions, working closely under the research theme "Accelerating Edge Intelligence for AI for Science" directed by Program Director Makoto Taiji at RIKEN's TRIP Headquarters. Here, MZT's proprietary genome-analysis accelerator, dubbed RASEN, will serve as the backbone for productization efforts. RASEN, designed specifically for this purpose, showcases the capacity to perform whole-genome sequencing in about five minutes on standard workstations, without relying on supercomputers or high-performance setups.

A Unique Approach to Genome Analysis

Since its inception in 2020, MZT has carved out a unique positioning in the market, primarily focusing on ASIC (Application-Specific Integrated Circuit) acceleration for genome analysis. Following successful technology validation in collaboration with Tohoku University and others, the startup is now firmly established as a pivotal research and development partner in the current initiative. MZT intends to integrate AI research results from RIKEN alongside Tohoku University’s insights into the RASEN architecture to bolster advancements in the field.

Future Vision and Applications

As MZT gears up for this innovative journey, the objective is not just technological advancement, but also real-world applications that can significantly enhance healthcare, drug discovery, and broader research infrastructures by 2029. The RASEN technology is already demonstrating impressive capabilities; independent validation against conventional methods showed a staggering 99.8% concordance with existing genome analysis techniques across numerous samples. This reinforces the notion that speed does not compromise accuracy—an essential factor in genomic research.

A Message of Commitment from Leadership

Keisuke Harashima, MZT's President and CEO, expressed his enthusiasm regarding the partnership: "It is a tremendous honor that we can lead the social implementation of this research theme through the acceleration of genome analysis via dedicated semiconductors -- a challenge we have pursued since MZT's founding." This commitment emphasizes MZT's strategic focus on transitioning RASEN from research-driven innovations to tangible, commercially viable products that can make a meaningful impact on global challenges, including healthcare accessibility and food security.

Conclusion

Mitate Zepto Technica's involvement in this forward-thinking R&D initiative not only underscores their continuing dedication to enhancing genomic analysis through advanced technology but also places them at the forefront of a rapidly evolving intersection between artificial intelligence and biotechnology. Their efforts in collaboration with esteemed institutions such as RIKEN and Tohoku University are set to propel the healthcare industry into a new era of efficiency and effectiveness in genomic research, making strides toward solving some of the most pressing challenges faced today.

For more insights about MZT and their innovative approach, visit their official website.